



Würtz, P., Wang, Q., Niironen, M., Tynkkynen, T., Tiainen, M., Drenos, F., Kangas, A. J., Soininen, P., Skilton, M. R., Heikkilä, K., Pouta, A., Kähönen, M., Lehtimäki, T., Rose, R. J., Kajantie, E., Perola, M., Kaprio, J., Eriksson, J. G., Raitakari, O. T., ... Auro, K. (2016). Metabolic signatures of birthweight in 18 288 adolescents and adults. *International Journal of Epidemiology*, 45(5), 1539-1550. <https://doi.org/10.1093/ije/dyw255>

Peer reviewed version

Link to published version (if available):

[10.1093/ije/dyw255](https://doi.org/10.1093/ije/dyw255)

[Link to publication record in Explore Bristol Research](#)

PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Oxford University Press at <https://academic.oup.com/ije/article/45/5/1539/2450944> . Please refer to any applicable terms of use of the publisher.

## University of Bristol - Explore Bristol Research

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: <http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

## Metabolic signatures of birth weight in 18 288 adolescents and adults

Peter Würtz<sup>1</sup>, Qin Wang<sup>1,2</sup>, Marjo Niironen<sup>3,4</sup>, Tuulia Tynkkynen<sup>1,2</sup>, Mika Tiainen<sup>1,2</sup>, Fotios Drenos<sup>5,6</sup>, Antti J Kangas<sup>1</sup>, Pasi Soininen<sup>1,2</sup>, Michael R Skilton<sup>7</sup>, Kauko Heikkilä<sup>8</sup>, Anneli Pouta<sup>9,10</sup>, Mika Kähönen<sup>11</sup>, Terho Lehtimäki<sup>12</sup>, Richard J Rose<sup>13</sup>, Eero Kajantie<sup>3,14,15</sup>, Markus Perola<sup>3,4</sup>, Jaakko Kaprio<sup>3,4,8</sup>, Johan G Eriksson<sup>3,16,17,18,19</sup>, Olli T Raitakari<sup>20,21</sup>, Debbie A Lawlor<sup>5,6</sup>, George Davey Smith<sup>5,6#</sup>, Marjo-Riitta Järvelin<sup>9,22#</sup>, Mika Ala-Korpela<sup>1,2,5,6#</sup>, Kirsi Auro<sup>3,4#</sup>

1. Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland
2. NMR Metabolomics Laboratory, School of Pharmacy, University of Eastern Finland, Kuopio, Finland
3. National Institute for Health and Welfare, Helsinki, Finland
4. Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland
5. Medical Research Council Integrative Epidemiology Unit at the University of Bristol, United Kingdom
6. School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom
7. Boden Institute of Obesity, Nutrition, Exercise, and Eating Disorders, University of Sydney, Sydney, Australia
8. Department of Public Health, University of Helsinki, Helsinki, Finland
9. Center for Life Course Health Research and Biocenter Oulu, University of Oulu, Oulu, Finland
10. Department of Children, Young People and Families, National Institute for Health and Welfare, Oulu, Finland
11. Department of Clinical Physiology, University of Tampere and Tampere University Hospital, Tampere, Finland
12. Department of Clinical Chemistry, Fimlab Laboratories and School of Medicine, University of Tampere, Tampere, Finland
13. Department of Psychological and Brain Sciences, Indiana University, Bloomington, Indiana, USA
14. Children's Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
15. Research Unit for Pediatrics, Dermatology, Clinical Genetics, Obstetrics and Gynecology, and Medical Research Unit Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland
16. Department of General Practice and Primary Health Care, University of Helsinki, Helsinki, Finland
17. Unit of General Practice, Helsinki University Hospital, Helsinki, Finland
18. Folkhälsan Research Center, Helsinki, Finland
19. Vasa Central Hospital, Vasa, Finland
20. Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland
21. Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, Finland
22. Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment and Health, Imperial College London, London, United Kingdom

# Joint senior authors on this work.

\*Corresponding author:

Dr. Peter Würtz, Computational Medicine, Faculty of Medicine,  
Aapistie 5A, PO Box 5000, 90014 University of Oulu, Finland;  
peter.wurtz@computationalmedicine.fi; Phone: +358-504670900

1 Table, 4 Figures. Main text: 3450 words. 49 References.

Supporting Information: Cohort descriptions, 1 Table, 8 Figures.

## ABSTRACT

**Background:** Lower birth weight is associated with increased susceptibility to cardiometabolic diseases in adulthood, but the underlying molecular pathways are incompletely understood. We examined associations of birth weight with a comprehensive metabolic profile measured in adolescents and adults.

**Methods:** High-throughput nuclear magnetic resonance metabolomics and biochemical assays were used to quantify 87 circulating metabolic measures in seven cohorts from Finland and the United Kingdom comprising altogether 18 288 individuals (mean age 26 years, range 15–75). Metabolic associations with birth weight were assessed by linear regression models adjusted for sex, gestational age, and age at blood sampling. The metabolic associations with birth weight were compared to the corresponding associations with adult body mass index (BMI).

**Results:** Lower birth weight adjusted for gestational age was adversely associated with cardiometabolic biomarkers, including lipoprotein subclasses, fatty acids, amino acids, and markers of inflammation and impaired liver function ( $P < 0.0015$  for 46 measures). Associations were consistent across cohorts with different ages at metabolic profiling, but the magnitudes were weak. The pattern of metabolic deviations associated with lower birth weight resembled the metabolic signature of higher adult BMI ( $R^2 = 0.77$ ) assessed at the same time as the metabolic profiling. The resemblance indicated that 1-kg lower birth weight is associated with similar metabolic aberrations as caused by 0.92-units higher BMI in adulthood.

**Conclusion:** Lower birth weight adjusted for gestational age is associated with adverse biomarker aberrations across multiple metabolic pathways. Coherent metabolic signatures between lower birth weight and higher adult adiposity suggest that shared molecular pathways may potentially underpin the metabolic deviations. However, the magnitudes of metabolic associations with birth weight are modest in comparison to the effects of adiposity, implying that birth weight is only a weak indicator of the metabolic risk profile in adulthood.

**Key words:** fetal programming, metabolic signatures, metabolomics, adiposity, fatty acids, amino acids.

**KEY MESSAGES:**

- Lower birth weight adjusted for gestational age is adversely associated with a wide range of established and emerging circulating cardiometabolic biomarkers in adulthood, including lipoprotein subclasses and their lipids, fatty acid balance, amino acids, and markers of inflammation and liver function.
- The metabolic associations are consistent across a wide age span from adolescence to retirement age, coherent for men and women, and broadly similar with and without adjustment for gestational age.
- Despite statistical significance of the metabolic associations with birth weight, the magnitudes of individual metabolic aberrations are weak for the variation in birth weight observed in general population cohorts.
- The overall metabolic association pattern with lower birth weight closely resembles the metabolic signature of higher adult adiposity. This may suggest that shared molecular pathways could underlie the fine-grained metabolic aberrations associated with both fetal growth and adiposity.
- 1-kg lower birth weight ( $\approx 2$  SD) is associated with similar adverse metabolic effects as caused by 0.92 higher BMI ( $\approx 0.25$  SD) in adulthood. These findings indicate that birth weight, as a surrogate marker for fetal growth, appears to only have modest effects on the adult metabolic risk profile in general population settings.

## INTRODUCTION

Birth weight is a marker of fetal growth rate and lower birth weight has been associated with increased rates of ischemic heart disease, stroke, and type 2 diabetes in adulthood.<sup>1-4</sup> These observations from multiple epidemiological studies have been interpreted according to the developmental-origins hypothesis, which proposes that fetal adaptive responses to suboptimal nutrition in utero may permanently alter the fetal organ structure and metabolic homeostasis, and hereby increase susceptibility to diseases that occur later in life.<sup>5,6</sup> This appears especially if fetal undernutrition is accompanied with abundant postnatal nutrition.<sup>7,8</sup> The developmental-origins hypothesis is supported by evidence from animal studies indicating that the foetus may adapt to an adverse intrauterine environment by slowing down growth and metabolism, which in turn has effects on adult organ size, structure and physiological function.<sup>6,9,10</sup> This adaptive strategy appears to increase short-term survival, but perhaps with adverse long-term consequences on health. Also human genetic evidence has linked fetal growth with adult metabolism and diabetes risk, yet the adverse influences of birth weight-lowering genes has been conflicting.<sup>11</sup> However, despite the epidemiological evidence and animal models, the underlying molecular mechanisms linking impaired fetal growth to adult disease are poorly understood and the potential causality remains unclear.

Life-long perturbations in causal metabolic risk factors induced via fetal response to a limiting intrauterine environment, e.g., elevated low-density lipoprotein (LDL) cholesterol, hypertension and type 2 diabetes, might represent pathways how impaired fetal growth could affect cardiometabolic risk in adulthood.<sup>2,3</sup> Numerous studies have shown associations between lower birth weight and adverse levels of metabolic risk factors in adulthood; these include insulin resistance and impaired glucose tolerance,<sup>12-14</sup> higher blood pressure<sup>15</sup> and low-grade inflammation.<sup>16</sup> Also adverse differences in cholesterol concentrations for lower birth weight have been reported in many studies across wide age ranges;<sup>15,17,18</sup> however, meta-analyses indicate modest magnitudes of association ( $\approx 0.05$  mmol/L higher total cholesterol per 1-kg lower birth weight).<sup>15,17</sup> Controversy prevails regarding the associations of birth weight with other circulating lipids, such as LDL cholesterol and triglyceride levels, and the potential relevance of such modest lipid aberrations as mediators of the adult disease risk has been questioned.<sup>15</sup>

The molecular effects of impaired fetal growth involve multiple metabolic pathways which extend beyond routine risk markers;<sup>6</sup> however, the wider influences on the systemic metabolic profile have not been assessed in large populations. Metabolomics is a powerful tool to study fine-grained molecular profiles and is therefore an attractive tool to study how birth weight is reflected on a comprehensive metabolic profile in adulthood. Nuclear magnetic resonance (NMR) metabolomics enables quantitative metabolic profiling of large blood sample collections.<sup>19</sup> This methodology provides detailed lipoprotein subclass profiling, as well as quantification of fatty acids and small molecules that have recently been linked with the risk for cardiovascular disease and diabetes.<sup>20-24</sup> These biomarkers could potentially serve as molecular intermediates between impaired intra-uterine growth and cardiometabolic risk. Studying the associations of birth weight with the detailed metabolic may therefore help to clarify the underlying mechanisms linking fetal growth with adult-onset disease and eventually help to inform how the risk could be mediated.<sup>25</sup> The metabolic profiling across multiple pathways simultaneously may further provide a more comprehensive view on the systemic effects of impaired fetal growth than would be obtained by examining individual biomarkers from a single molecular pathway. However, only few metabolomics studies on birth weight have been conducted to date. These studies have been limited to a very small number of individuals, have focused on preterm birth at very low birth weight, and primarily assessed associations with metabolites measured from umbilical cord blood.<sup>26-28</sup> No study has previously used metabolomics to assess the role of birth weight on adult metabolic profiles in large general population settings.

To characterize metabolic signatures of lower birth weight, we used serum NMR metabolomics of 18 288 individuals from seven cohorts, which together cover individuals from adolescence to the end of working age. We further compared how the metabolic association pattern with birth weight resembles the association pattern of adiposity in adulthood for the same extensive panel of metabolic measures.

## **METHODS**

### *Study populations*

The study comprised six Finnish cohorts and one cohort from the United Kingdom (**Table 1**): the children part of the Avon Longitudinal Study of Parents and Children (ALSPAC; n=2874; metabolic profiles measured from blood samples drawn at age 17)<sup>29</sup>; the Northern Finland Birth Cohort (NFBC) 1986 (n=5579; age 16)<sup>30</sup> and NFBC 1966 (n=5412; age 31)<sup>31</sup>, the Cardiovascular Risk in Young Finns Study (YFS; n=2273; age 24–48)<sup>32</sup>, the FinnTwin studies FT12 (n=767, age 21–25) and FT16 (n=495, age 23–30)<sup>33</sup>, and the Helsinki Birth Cohort Study (HBCS; n=890; age 62–75)<sup>8</sup>. Details of the cohorts related to the present study are described in the **Supplementary Methods** (available as Supplementary data at *IJE* online). Birth weight and gestational age were assessed by a midwife, birth medical records or antenatal care. Gestational age was defined as a categorical variable indicating completed weeks of gestation. Out of 19 622 eligible individuals with metabolic profiling data, 18 649 had complete data on birth weight, gestational age, and adult body mass index (BMI). BMI was measured in adolescence or adulthood at the same time as the blood sampling for metabolic profiling in all cohorts (henceforth denoted adult BMI). Women who were pregnant (n=115) and individuals on lipid-lowering medication (n=246) at the time of metabolic profiling were excluded, leaving 18 288 individuals for the present analysis. All study participants provided informed consent, and study protocols were approved by the local ethical committees.

#### *Lipid and metabolite quantification*

Fasting blood samples were collected as part of the clinical examinations in adolescence and in adulthood and stored as serum or EDTA plasma at -80°C for subsequent biomarker profiling as detailed in **Supplementary Methods**. Altogether 87 metabolic measures were analysed for the present study. A high-throughput NMR metabolomics platform was used for the quantification of 77 metabolic measures.<sup>19</sup> This metabolomics platform provides simultaneous quantification of routine lipids, lipid concentrations of 14 lipoprotein subclasses and major subfractions, and further quantifies abundant fatty acids, amino acids, ketone bodies and gluconeogenesis-related metabolites in absolute concentration units (**Table S1**). The metabolic profiling therefore includes both routine risk markers and novel metabolic biomarkers that have not previously been examined in relation to birth weight. The NMR metabolomics platform has been extensively applied for biomarker profiling in epidemiological studies<sup>20,21,23–25,34,35</sup> and details of the experimentation have been described elsewhere.<sup>19,36</sup> In addition to the NMR metabolomics measures, 10 metabolic markers

related to inflammation, liver function and hormone balance, assayed in two or more of the cohorts, were analysed as part of the comprehensive metabolic profile (**Supplementary Methods**).<sup>25</sup> Mean (SD) concentrations of the metabolic measures in each cohort are listed in **Table S2**.

### *Statistical analyses*

Metabolic measures with skewed distributions (skewness>2) were normalized by log-transformation prior to analyses. Linear regression models for each metabolite were tested with birth weight as the explanatory variable and the metabolite concentration as an outcome. Associations were adjusted for sex, age at blood sampling, and gestational age. Adjusting birth weight for gestational age broadly means that the birth weight variable may be interpreted in terms of growth rate. Results were analysed separately for the seven cohorts and combined using fixed effect inverse-variance weighted meta-analysis after verifying the consistency across the seven cohorts. Association magnitudes are quantified in SD-units of metabolite concentration per 1-kg lower birth weight ( $\approx 2$  SD). Due to the correlated nature of the metabolic measures, >95% of the variation in the 87 measures was explained by at most 34 principal components in each cohort. Multiple testing correction therefore accounted for 34 independent tests using the Bonferroni method, resulting in  $P < 0.0015$  denoted statistically significant.

The pattern of metabolic associations with birth weight was compared to the corresponding cross-sectional metabolic associations with adult BMI, using the same approach as used for birth weight but without adjustment for gestational age. The overall correspondence between the metabolic association patterns of birth weight and adult BMI were summarized using the  $R^2$  and slope of the linear fit.<sup>25,35</sup>

To examine whether there was evidence for curvilinear associations we assessed the shape of the associations using local quadratic regression fitting, with each smoothing function evaluated at 25 points through the range of birth weight. Absolute concentrations of each metabolic measure were first regressed for age and sex, and the resulting residuals were pooled and rescaled to absolute units prior to fitting.<sup>35</sup>



## RESULTS

The study comprised 18 288 adolescents and adults from five general population cohorts and two twin cohorts from Finland and the UK (**Table 1**). Distributions of birth weight for each cohort are illustrated in **Figure S1**. Only 1% of the singleton participants had a birth weight of <2 kg. Birth weight was correlated with adult BMI ( $r=0.09$ ) in a broadly linear manner for most of the cohorts (**Figure S2**).

### *Lipoprotein measures*

Associations of birth weight with 43 lipoprotein measures are shown in **Figure 1**. In the meta-analysis, birth weight was robustly associated with numerous lipoprotein measures ( $P<0.0015$  for 25 measures). While the associations of routine cholesterol measures were of modest magnitudes, somewhat stronger associations were observed for many of the more detailed lipid measures. Lower birth weight was associated with higher circulating apolipoprotein B (apoB) and total lipid concentrations in the apoB-carrying particles (very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL) and LDL). The strongest associations with lipoprotein subclasses were observed for lipids in medium and small VLDL particles. Associations were weaker for lipids in IDL and LDL particles, albeit with stronger association magnitude for lipids in small LDL. Associations were more heterogeneous for lipids in high-density lipoprotein (HDL) particles: lower birth weight was associated with lower concentrations of circulating lipids in large HDL particles, but with higher concentrations of those in small HDL (i.e., in the same direction as for the apoB-carrying lipoproteins). Birth weight was also robustly associated with the average size of the lipoprotein particles, with increased VLDL size and decreased LDL and HDL size related to lower birth weight. Within a given lipoprotein class, associations with birth weight tended to be stronger for triglycerides than for cholesterol and phospholipid levels.

To enable comparison of birth weight associations across the metabolic measures, all association magnitudes are scaled to SD-units of metabolite concentration per 1-kg lower birth weight. The corresponding associations in absolute units, e.g., mmol/L per kg, are listed in **Table S1**. For instance, total triglyceride concentration was among the measures most

strongly associated with birth weight, with each 1-kg lower birth weight being associated with 0.04 mmol/L higher serum triglyceride concentration.

#### *Fatty acids*

Associations of birth weight with 16 fatty acid measures are shown in **Figure 2**. Lower birth weight was robustly associated with higher absolute concentration of all fatty acids assayed except docosahexaenoic acid. The strongest associations were observed for total, saturated and monounsaturated fatty acids (MUFA), which displayed association magnitudes comparable to that of apoB. Somewhat weaker associations were observed for omega-6 and omega-3 fatty acids. For the fatty acid ratios, the proportion of saturated fatty acids and MUFAs tended to be higher among individuals with lower birth weight, whereas the proportion of omega-6 fatty acids were lower.

#### *Non-lipid metabolic measures*

Associations of birth weight with 28 non-lipid metabolites and other metabolic measures are shown in **Figure 3**. Lower birth weight was associated with higher concentrations of alanine, branched-chain and aromatic amino acids. These amino acid associations with birth weight were of comparable magnitude to that of apoB. Lower birth weight was not robustly associated with glucose, while other gluconeogenesis-related metabolites displayed stronger associations. Lower birth weight was also robustly associated with higher levels of insulin and certain markers for low-grade inflammation and impaired liver function.

#### *Resemblance between metabolic signatures of birth weight and adult BMI*

The overall pattern of metabolic associations with lower birth weight was reminiscent of the metabolic association pattern with adiposity assessed at the same time as the blood sampling (**Figure S3**).<sup>25,37,38</sup> We therefore compared the metabolic associations of birth weight to the corresponding metabolic associations of adult BMI (**Figure 4**). The resemblance between the metabolic association patterns was high, as indicated by the goodness-of-fit being  $R^2=0.77$ . The slope denotes that 1-kg lower birth weight is associated with similar magnitudes of metabolic aberrations as those linked with 0.92 higher adult BMI-units ( $\text{kg}/\text{m}^2$ ). A similar resemblance with the association pattern with lower birth weight was observed for higher adult weight ( $R^2=0.75$ ), indicating that metabolic associations with 1-kg

lower birth weight were similar to those linked with 3.1 kg higher adult weight. In contrast, the pattern of metabolic associations with adult height was considerably different (**Figure S4**;  $R^2=0.17$ ).

#### *Consistency and sensitivity analyses*

Despite differences in age at blood sampling, the associations of birth weight with the metabolic measures were generally consistent across the seven cohorts and displayed little evidence of heterogeneity (**Figure S5**). The results were also generally similar and statistically consistent for men and women (**Figure S6**). The association magnitudes were also similar (on average 5% weaker) if omitting participants within the lowest percentile (birth weight <2.0 kg) and highest percentile (birth weight >4.7 kg). The metabolic associations were slightly weaker (on average 8%) if omitting gestational age as a covariate (**Figure S7**). However, gestational age modelled as the primary exposure was essentially not associated with metabolic aberrations in adulthood (**Figure S7**), indicating that growth rate rather than length of gestation is important in relation to metabolic deviations.<sup>39</sup> The metabolic associations with birth weight followed a similar pattern if adjusting for adult BMI (assessed at the same time as the blood sampling), however this adjustment increased the magnitude of association by 58% on average (**Figure S8**). The continuous shapes of the metabolic associations with birth weight are illustrated in **Figure S9**. Most associations were approximately linear across the birth weight distribution, justifying the use of linear regression modelling.

## **DISCUSSION**

In this meta-analysis of 18 288 individuals, lower birth weight (adjusted for gestational age) was adversely associated with numerous blood-based biomarkers across the comprehensive metabolic profile, including lipoprotein subclass measures, fatty acid composition, amino acids as well as markers of inflammation and liver function. The metabolic associations were all in a direction of higher risk for diabetes and cardiovascular disease, both for established risk factors and emerging biomarkers. The associations were coherent across seven cohorts with a wide age range at metabolic profiling, from adolescence through adulthood, suggesting that these metabolic aberrations are lifelong. These findings are coherent with the developmental origins hypothesis, proposing long-term alterations in metabolic

homeostasis.<sup>6</sup> However, although many of the associations were statistically robust in this large study sample, the small association magnitudes indicate that the influences of birth weight on systemic metabolism are modest.

The wide palette of the metabolic deviations associated with lower birth weight have previously been linked with increased risk for cardiometabolic diseases.<sup>19-24</sup> Among the lipoprotein measures adversely associated with lower birth weight were both cholesterol-rich LDL particles and triglyceride-rich VLDL particles. Genetic evidence suggests that both these types of apoB-carrying lipoproteins are causally related to ischemic heart disease.<sup>40</sup> Associations with routine cholesterol measures were modest, in line with prior meta-analyses that have questioned the relevance of associations between birth weight and circulating lipids.<sup>15,17,41</sup> Although the lipoprotein subclass profiling indicated somewhat stronger and statistically robust associations with several more detailed lipid measures, the associations were nevertheless in line with the overall weak metabolic aberrations.

Increased circulating levels of omega-3 fatty acids have been associated with lower risk for future cardiovascular disease events.<sup>20</sup> Whilst dietary supplementation of omega-3 fatty acids has been suggested as intervention for people born with impaired fetal growth,<sup>42</sup> the serum levels of omega-3 have not been robustly linked with birth weight. Here, the association of birth weight was flat for the proportion of omega-3 fatty acids relative to total fatty acids. However, the proportion of omega-6 fatty acids — also inversely associated with the risk for cardiovascular disease<sup>20</sup> and diabetes<sup>23</sup> — was decreased in relation with lower birth weight. The small magnitudes of the fatty acid perturbations are unlikely to substantially mediate the associations between lower birth weight and increased susceptibility to cardiometabolic diseases.

Recent metabolomics studies have shown that amino acids and many other circulating metabolites are predictive of the risk for diabetes, cardiovascular disease, and all-cause mortality.<sup>20-22,24,43</sup> For instance, elevated circulating levels of branched-chain and aromatic amino acids have been robustly associated with insulin resistance, hyperglycaemia and diabetes risk in a number of studies.<sup>22,24,43</sup> Aromatic amino acids have also been shown to be predictors of cardiovascular event risk, even more strongly than LDL cholesterol.<sup>20</sup> All these

amino acids were found to be elevated for lower birth weight, i.e., in the direction consistent with higher metabolic risk. Lower birth weight was also related to higher concentrations of markers for impaired liver function, insulin resistance and chronic inflammation. These metabolic markers are also predictive for the risk of a broad span of chronic diseases and all-cause mortality.<sup>21,44,45</sup> Importantly, while the individual biomarker associations with birth weight are all modest, the combined metabolic aberrations may in concert potentially contribute to mediate the relation between birth weight and cardiometabolic disease risk.

Elevated BMI has recently been shown to have a causal metabolic signature across biomarkers from multiple pathways.<sup>25</sup> This metabolic signature of adiposity is highly reminiscent of the pattern of metabolic associations here linked with lower birth weight. The similarity in the detailed association patterns illustrates how comprehensive metabolic profiling may help to pinpoint molecular connections between the metabolic effects of different risk factors. The resemblance between the metabolic signatures allows to summarize the metabolic aberrations linked with birth weight in relation to the effects of adiposity: 1-kg lower birth weight in the general population is associated with similar metabolic deviations as those caused by 0.92 kg/m<sup>2</sup> higher BMI in adulthood. The consistency with the metabolic association pattern for birth weight was driven by adult weight rather than height, suggesting that the underlying mechanisms are not primarily related to stature. A 1-kg difference in birth weight is substantial, corresponding to almost 2 SDs. A similar variance in adulthood BMI (i.e., a 2 SD greater adult BMI) is associated with 8-fold stronger metabolic deviations, indicating much more pronounced metabolic perturbations associated with higher adult adiposity than those linked with lower birth weight.

The prominent correspondence between the metabolic signatures of lower birth weight and elevated BMI leads us to speculate that impaired fetal growth and adiposity may have shared molecular pathways underlying the fine-grained metabolic aberrations. As a corollary of this hypothesis, we anticipate that the causal effects of BMI on also other molecular markers<sup>46</sup> and physiological factors can be used to predict the anticipated association of birth weight with these same outcomes. For instance, genetic evidence indicates that the lifelong causal effect of BMI on systolic blood pressure is 0.9 mmHg per higher BMI-unit;<sup>25,47</sup>

based on the above hypothesis we extrapolate that the association of birth weight with systolic blood pressure would be  $0.9 \times 0.92 \approx 0.8$  mmHg per 1-kg lower birth weight. This is broadly consistent with the association observed in meta-analysis.<sup>37,38</sup> Since our results indicate that the metabolic perturbations associated with birth weight are present across the lifecourse, it is important that such extrapolation of birth weight associations with other risk markers is based on lifelong effects of BMI, e.g., from genetic estimates. Based in this principle, it is also possible to estimate the association of birth weight with cardiometabolic disease risk by comparison to the risk effects caused by BMI. Accordingly, 0.92 BMI-units is causally associated with  $\approx 10\%$  higher risk for ischemic heart disease,<sup>48,49</sup> which is consistent with meta-analysis results on the risk magnitude for ischemic heart disease per 1-kg lower birth weight.<sup>2</sup> Similarly, 0.92 BMI-units is causally associated with 24–33% higher risk for type 2 diabetes<sup>47,50</sup>, which again is consistent with meta-analysis estimates of the diabetes risk per 1-kg lower birth weight.<sup>3</sup> These results seem to suggest that the comprehensive metabolic effects corresponding to as little as 0.92 BMI-units, affecting over the lifecourse, may be sufficient to explain the association of birth weight with cardiometabolic disease risk in adulthood. However, we acknowledge that the specific mechanisms linking birth weight and adiposity to cardiometabolic outcomes may be different despite the shared metabolic signatures.

It is of note that although birth weight was  $\approx 700$  grams lower in the twin cohorts than in singletons, the metabolite concentrations and the pattern of metabolic associations with birth weight were generally similar to the other cohorts (**Table S2** and **Figure S5**). This is consistent with no difference in diabetes prevalence or overall mortality among twin individuals compared to singletons<sup>51,52</sup>, supporting our conclusion that lower birth weight per se has a minor long-term impact on the systemic metabolic risk profile. However, direct comparison of potential small metabolic differences due to lower birth weight in twins is not feasible in this study due to confounding differences in cohort characteristics as well as variations between cohorts in pre-analytic sample handling, storage duration and type of blood specimen (serum vs. plasma). The metabolic associations with birth weight were stronger (on average 58%) if adjusting for adult BMI, in line with prior studies on metabolic risk factors,<sup>3,15,17,37</sup> suggesting that birth weight in relation to current weight is more relevant for adulthood metabolic aberrations than birth weight alone. The adjustment for adult BMI

has been considered inappropriate due to the correlation of BMI with both birth weight and metabolite levels.<sup>37,53</sup> However, the BMI-adjusted results may be interpreted as a measure of change in size between birth and adulthood,<sup>53,54</sup> and the stronger metabolic associations observed here accordingly indicates a contributing role of postnatal growth. Further studies on the comprehensive metabolic effects of growth in infancy may clarify the role of compensatory growth and other proposed interactions with birth weight on the metabolic profile in adulthood.<sup>8,54</sup>

Strengths of this study include the large sample size, comprising seven cohorts with quantitative metabolomics data. Birth weight was obtained from birth medical records for 88% of the study population, which minimizes bias from self-reporting, and data on gestational age allowed accounting for lower birth weight caused by prematurity. The broadly coherent results across cohorts of a wide age range provided a view to the life-course effects of birth weight. However, the general population nature of the cohorts analysed prevents us from making conclusions regarding the specific metabolic effects of infants born preterm, or those with severe fetal growth restriction.<sup>28</sup> Birth weight has limitations as a marker of impaired fetal growth, however it is the surrogate most widely reported in large population cohorts, and it has a high correlation with other markers of size at birth.<sup>17</sup> We acknowledge that we cannot assume that impaired fetal growth is causal for the adulthood metabolic aberrations observed. For example, genetic analyses support a causal role for maternal smoking in pregnancy and higher blood pressure resulting on lower infant birth weight, which could potentially contribute to explain the weak inverse associations with metabolic risk markers observed here.<sup>55,56</sup> Given the predominantly young age of the study participants we were not able to test whether the metabolic aberrations related to birth weight could mediate the relationship to cardiometabolic disease outcomes. Other metabolomics technologies may eventually provide further insights into the intricate metabolic effects of fetal growth, however the present study demonstrates that large sample size is required to robustly assess the weak associations. Finally, it is important to recognize that information on antenatal nutrition and other factors that might underlie the relationships of birth weight with metabolic outcomes might highlight associations of a larger magnitude or potentially greater importance than suggested by our results.

In conclusion, comprehensive metabolic profiling of large cohorts identified associations between lower birth weight (adjusted for gestational age) and adverse circulating levels of a wide panel of circulating cardiometabolic risk markers in adulthood. The overall metabolic signature of lower birth weight closely resembled the metabolic effects of higher BMI, suggesting that shared molecular pathways may underpin the perturbed metabolic profile related to both fetal growth and adiposity. Nevertheless, the aberrations were of modest magnitude, with similar metabolic perturbations related to 1-kg lower birth weight as those caused by lifelong effects of  $\approx 3$  kg higher body weight in adulthood. These results indicate that birth weight is only a weak indicator of the metabolic risk profile in adulthood.



## **Supplementary Data (available at *IJE* online)**

**Supplementary Methods: Study populations.**

**Table S1. Mean (SD) metabolic concentrations, and associations with birth weight in absolute concentration units.**

**Table S2. Mean (SD) concentrations of metabolites in each cohort.**

**Figure S1. Birth weight distribution in each cohort.**

**Figure S2. Adult body mass index as a function of birth weight in each cohort.**

**Figure S3. Metabolic associations with adulthood body mass index.**

**Figure S4. Metabolic associations with adulthood height.**

**Figure S5. Metabolic associations with birth weight in each cohort.**

**Figure S6. Metabolic associations with birth weight for men and women.**

**Figure S7. Metabolic associations with birth weight without adjustment for gestational age and gestational age as predictor of adulthood metabolic aberrations.**

**Figure S8. Metabolic associations with birth weight adjusted for adult BMI.**

**Figure S9. Curvilinear shapes of metabolic associations with birth weight.**

## REFERENCES

1. Barker DJ, Osmond C, Golding J, Kuh D, Wadsworth ME. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. *BMJ* 1989;**298**:564–567.
2. Huxley R, Owen CG, Whincup PH, et al. Is birth weight a risk factor for ischemic heart disease in later life? *Am J Clin Nutr* 2007;**85**:1244–1250.
3. Whincup PH, Kaye SJ, Owen CG, et al. Birth weight and risk of type 2 diabetes: a systematic review. *JAMA* 2008;**300**:2886–2897.
4. Risnes KR, Vatten LJ, Baker JL, et al. Birthweight and mortality in adulthood: a systematic review and meta-analysis. *Int J Epidemiol* 2011;**40**:647–661.
5. Barker DJP. Fetal origins of coronary heart disease. *BMJ* 1995;**311**:171–174.
6. Gluckman PD, Hanson MA, Cooper C, Thornburg KL. Effect of in utero and early-life conditions on adult health and disease. *N Engl J Med* 2008;**359**:61–73.
7. Barker D. Fetal origins of adult disease: strength of effects and biological basis. *Int J Epidemiol* 2002;**31**:1235–1239.
8. Eriksson JG. Early growth and coronary heart disease and type 2 diabetes: findings from the Helsinki Birth Cohort Study (HBCS). *Am J Clin Nutr* 2011;**94**(6\_Suppl):1799S–1802S.
9. Bateson P, Barker D, Clutton-Brock T, et al. Developmental plasticity and human health. *Nature* 2004;**430**:419–421.
10. Ozanne SE, Hales CN. Lifespan: Catch-up growth and obesity in male mice. *Nature* 2004;**427**:411–412.
11. Horikoshi M, Yaghootkar H, Mook-Kanamori DO, et al. New loci associated with birth weight identify genetic links between intrauterine growth and adult height and metabolism. *Nat Genet* 2013;**45**:76–82.
12. Lithell HO, McKeigue PM, Berglund L, Mohsen R, Lithell UB, Leon DA. Relation of size at birth to non-insulin dependent diabetes and insulin concentrations in men aged 50-60 years. *BMJ* 1996;**312**:406–410.
13. McKeigue PM, Lithell HO, Leon DA. Glucose tolerance and resistance to insulin-stimulated glucose uptake in men aged 70 years in relation to size at birth. *Diabetologia* 1998;**41**:1133–1138.
14. Hales CN, Barker DJ. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. *Diabetologia* 1992;**35**:595–601.
15. Huxley R, Owen CG, Whincup PH, Cook DG, Colman S, Collins R. Birth weight and subsequent cholesterol levels: exploration of the ‘fetal origins’ hypothesis. *JAMA* 2004;**292**:2755–2764.
16. Tzoulaki I, Jarvelin MR, Hartikainen AL, et al. Size at birth, weight gain over the life course, and low-grade inflammation in young adulthood: northern Finland 1966 birth cohort study. *Eur Heart J* 2008;**29**:1049–1056.
17. Owen CG, Whincup PH, Odoki K, Gilg JA, Cook DG. Birth weight and blood cholesterol level: a

study in adolescents and systematic review. *Pediatrics* 2003;**111**:1081–1089.

18. Lawlor DA, Owen CG, Davies AA, et al. Sex differences in the association between birth weight and total cholesterol. A meta-analysis. *Ann Epidemiol* 2006;**16**:19–25.
19. Soininen P, Kangas AJ, Würtz P, Suna T, Ala-Korpela M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. *Circ Cardiovasc Genet* 2015;**8**:192–206.
20. Würtz P, Havulinna AS, Soininen P, et al. Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. *Circulation* 2015;**131**:774–785.
21. Fischer K, Kettunen J, Würtz P, et al. Biomarker profiling by nuclear magnetic resonance spectroscopy for the prediction of all-cause mortality: An observational study of 17,345 persons. *PLoS Med* 2014;**11**(2):e1001606.
22. Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. *Nat Med* 2011;**17**:448–453.
23. Mahendran Y, Cederberg H, Vangipurapu J, et al. Glycerol and fatty acids in serum predict the development of hyperglycemia and type 2 diabetes in Finnish men. *Diabetes Care* 2013;**36**:3732–3738.
24. Tillin T, Hughes AD, Wang Q, et al. Diabetes risk and amino acid profiles: cross-sectional and prospective analyses of ethnicity, amino acids and diabetes in a South Asian and European cohort from the SABRE (Southall And Brent REvisited) Study. *Diabetologia*. 2015;**58**:968–979.
25. Würtz P, Wang Q, Kangas AJ, et al. Metabolic signatures of adiposity in young adults: Mendelian randomization analysis and effects of weight change. *PLoS Med* 2014;**11**:e1001765.
26. Moco S, Collino S, Rezzi S, Martin F-PJ. Metabolomics perspectives in pediatric research. *Pediatr Res* 2013;**73**:570–576.
27. Fanos V, Atzori L, Makarenko K, Melis GB, Ferrazzi E. Metabolomics application in maternal-fetal medicine. *Biomed Res Int* 2013;**2013**:720514.
28. Hovi P, Kajantie E, Soininen P, et al. Lipoprotein subclass profiles in young adults born preterm at very low birth weight. *Lipids Health Dis* 2013;**12**:57.
29. Boyd A, Golding J, Macleod J, et al. Cohort Profile: the ‘children of the 90s’ – the index offspring of the Avon Longitudinal Study of Parents and Children. *Int J Epidemiol* 2013;**42**:111–127.
30. Kantomaa MT, Stamatakis E, Kankaanpää A, et al. Physical activity and obesity mediate the association between childhood motor function and adolescents' academic achievement. *Proc Natl Acad Sci USA* 2013;**110**:1917–1922.
31. Järvelin M-R, Sovio U, King V, et al. Early life factors and blood pressure at age 31 years in the 1966 northern Finland birth cohort. *Hypertension* 2004;**44**:838–846.
32. Nuotio J, Oikonen M, Magnussen CG, et al. Cardiovascular risk factors in 2011 and secular trends since 2007: The Cardiovascular Risk in Young Finns Study. *Scand J Public Health*

- 2014;**42**:563–571.
33. Jelenkovic A, Bogl LH, Rose RJ, et al. Association of height and pubertal timing with lipoprotein subclass profile: Exploring the role of genetic and environmental effects. *Am J Hum Biol* 2013;**25**:465–472.
  34. Auro K, Joensuu A, Fischer K, et al. A metabolic view on menopause and ageing. *Nat Commun* 2014;**5**:4708.
  35. Würtz P, Cook S, Wang Q, Tiainen M, Tynkkynen T. Metabolic profiling of alcohol consumption in 9778 young adults. *Int J Epidemiol* 2016. In press, doi: 10.1093/ije/dyw175.
  36. Soininen P, Kangas AJ, Würtz P, et al. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. *Analyst* 2009;**134**:1781.
  37. Huxley R, Neil A, Collins R. Unravelling the fetal origins hypothesis: is there really an inverse association between birthweight and subsequent blood pressure? *Lancet* 2002;**360**:659–665.
  38. Gamborg M, Byberg L, Rasmussen F, et al. Birth weight and systolic blood pressure in adolescence and adulthood: Meta-regression analysis of sex- and age-specific results from 20 Nordic studies. *Am J Epidemiol* 2007;**166**:634–645.
  39. Leon DA, Lithell HO, Vagero D, et al. Reduced fetal growth rate and increased risk of death from ischaemic heart disease: cohort study of 15 000 Swedish men and women born 1915–29. *BMJ* 1998;**317**:241–245.
  40. Do R, Willer CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. *Nat Genet* 2013;**45**:1345–1352.
  41. Lauren L, Järvelin M-R, Elliott P, et al. Relationship between birthweight and blood lipid concentrations in later life: evidence from the existing literature. *Int J Epidemiol* 2003;**32**:862–876.
  42. Skilton MR, Phang M. From the alpha to the omega-3: breaking the link between impaired fetal growth and adult cardiovascular disease. *Nutrition* 2016 **32**:725–31
  43. Stančáková A, Civelek M, Saleem NK, et al. Hyperglycemia and a common variant of GCKR are associated with the levels of eight amino acids in 9,369 Finnish men. *Diabetes* 2012;**61**:1895–1902.
  44. Fraser A, Harris R, Sattar N, Ebrahim S, Davey Smith G, Lawlor DA. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. *Diabetes Care* 2009;**32**:741–750.
  45. Lawlor DA, Fraser A, Ebrahim S, Smith GD. Independent associations of fasting insulin, glucose, and glycated haemoglobin with stroke and coronary heart disease in older women. *PLoS Med* 2007;**4**:e263.
  46. Ho JE, Larson MG, Ghorbani A, et al. Metabolomic profiles of body mass index in the Framingham Heart Study reveal distinct cardiometabolic phenotypes. *PLoS ONE* 2016;**11**:e0148361.
  47. Fall T, Hägg S, Mägi R, et al. The role of adiposity in cardiometabolic traits: a Mendelian

- randomization analysis. *PLoS Med* 2013;**10**:e1001474.
48. Nordestgaard BG, Palmer TM, Benn M, et al. The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a Mendelian randomisation approach. *PLoS Med*. 2012;**9**:e1001212.
  49. Hägg S, Fall T, Ploner A, et al. Adiposity as a cause of cardiovascular disease: a Mendelian randomization study. *Int J Epidemiol* 2015;**44**:578–586.
  50. Holmes MV, Lange LA, Palmer T, et al. Causal effects of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis. *Am J Hum Genet* 2014 **94**:198–208.
  51. Christensen K, Vaupel JW, Holm NV, Yashin AI. Mortality among twins after age 6: fetal origins hypothesis versus twin method. *BMJ* 1995;**310**:432–436.
  52. Petersen I, Nielsen M, Beck-Nielsen H. No evidence of a higher 10 year period prevalence of diabetes among 77,885 twins compared with 215,264 singletons from the Danish birth cohorts 1910–1989. *Diabetologia* 2011;**54**:2016–2024.
  53. Lucas A, Fewtrell MS, Cole TJ. Fetal origins of adult disease – the hypothesis revisited. *BMJ* 1999;**319**:245–249.
  54. Leon DA, Koupilova I, Lithell HO, et al. Failure to realise growth potential in utero and adult obesity in relation to blood pressure in 50 year old Swedish men. *BMJ* 1996;**312**:401–406.
  55. Tyrrell J, Huikari V, Christie JT, et al. Genetic variation in the 15q25 nicotinic acetylcholine receptor gene cluster (CHRNA5-CHRNA3-CHRNA4) interacts with maternal self-reported smoking status during pregnancy to influence birth weight. *Hum Mol Genet* 2012;**21**:5344–5358.
  56. Tyrrell J, Richmond RC, Palmer TM, et al. Genetic evidence for causal relationships between maternal obesity-related traits and birth weight. *JAMA* 2016;**315**:1129–1140.

## **SOURCES OF FUNDING**

This study was supported by the Strategic Research Funding from the University of Oulu, Finland, the Sigrid Juselius Foundation, the Novo Nordisk Foundation, the Yrjö Jahnsson Foundation, the Finnish Diabetes Research Foundation, the Finnish Medical Foundation, the Paulo Foundation, Biocenter Oulu, Finland, and the UK Medical Research Council via the University of Bristol Integrative Epidemiology Unit (IEU; MC\_UU\_12013/1 and MC\_UU\_12013/5). The Cardiovascular Risk in Young Finns Study is supported by the Academy of Finland (grants 286284, 134309, 126925, 121584, 124282, 129378, 117787, and 41071), Finnish Foundation for Cardiovascular Research, Oulu, Helsinki, Kuopio, Tampere, and Turku University Central Hospital Medical Funds, the Paavo Nurmi Foundation, the Juho Vainio Foundation, the Finnish Cultural Foundation, the Finnish Funding Agency for Technology and Innovation. The Northern Finland Birth Cohorts of 1966 and 1986 has received financial support from Academy of Finland, University Hospital Oulu, Biocenter Oulu, University of Oulu, the European Commission (EURO-BLCS, Framework 5 award QLG1-CT-2000-01643, ENGAGE project and grant agreement HEALTH-F4-2007-201413, EurHEALTHAgeing (277849), European Regional Developmental Fund), EU H2020-PHC-2014 (Grant no. 633595), DynaHEALTH, NHLBI grant 5R01HL087679-02 through the STAMPEED program (1RL1MH083268-01), NIH/NIMH (5R01MH63706:02), Stanley Foundation, the UK Medical Research Council, and Wellcome Trust. The UK Medical Research Council and Wellcome Trust (Grant: 102215/2/13/2) and the University of Bristol provide core support for ALSPAC. The contribution of DAL to this study is supported by grants from the US National Institute of Health (R01 DK10324), European Research Council (ObesityDevelop; Grant no. 669545) and UK National Institute for Health Research (NF-SI-0166-10196). FD, DAL, GDS and MAK work in a Unit that is supported by the University of Bristol and UK Medical Research Council (MC\_UU\_12013/1 and MC\_UU\_12013/5). The FinnTwin-12 and FinnTwin-16 studies have received support from the National Institute on Alcohol Abuse and Alcoholism (R37-AA12502, R01-AA09203 and K05-AA00145). The views expressed in this paper are those of the authors and not necessarily any funding body.

## **DISCLOSURES**

PW, AJK, PS, and MAK are shareholders of Brainshake Ltd., a company offering NMR-based metabolic profiling ([www.brainshake.fi](http://www.brainshake.fi)). PW, TT, MT, PS, and AJK report employment relation with Brainshake Ltd. DAL has received funding for biomarker research, unrelated to this paper, from Roche Diagnostics and Ferring Pharmaceuticals. KA is currently employed by GSK. No other authors reported disclosures.

**Table 1. Characteristics of the seven cohorts.**

Characteristics	NFBC 1986	ALSPAC Children	Finn-Twin FT12	Finn-Twin FT16	NFBC 1966	Young Finns Study	Helsinki Birth Cohort Study
Number of individuals	5579	2874	767	495	5412	2273	890
Men [%]	50.4	48.4	41.2	51.1	49.9	44.7	43.9
Age at blood sampling [years]	16.1 (0.4)	17.8 (0.4)	22.4 (0.6)	26.2 (1.3)	31.2 (0.4)	39.2 (6.1)	66.3 (2.9)
Birth weight [g]	3562 (541)	3426 (546)	2703 (507)	2673 (495)	3498 (523)	3508 (543)	3432 (470)
Gestational age [week]	39.4 (1.8)	39.4 (1.6)	36.9 (2.2)	36.9 (2.5)	40.0 (1.9)	38.6 (1.2)	40.0 (1.5)
Adult body mass index [kg/m <sup>2</sup> ]	21.2 (3.4)	23.0 (3.9)	23.3 (3.9)	23.8 (4.0)	25.6 (4.1)	26.3 (4.9)	27.0 (4.1)
Systolic blood pressure [mm Hg]	116 (13)	115 (10)	–	–	125 (13)	119 (14)	143 (19)
Total-C [mmol/L]	4.3 (0.8)	3.8 (0.7)	4.7 (0.9)	5.0 (0.9)	5.0 (1.0)	5.1 (0.9)	6.1 (1.0)
HDL-C [mmol/L]	1.4 (0.3)	1.4 (0.2)	1.8 (0.4)	1.8 (0.4)	1.5 (0.4)	1.3 (0.3)	1.7 (0.4)
Triglycerides [mmol/L]	0.7 [0.6-1.0]	0.8 [0.7-1.0]	0.9 [0.7-1.2]	1.2 [0.9-1.62]	1.0 [0.7-1.4]	1.1 [0.8-1.5]	1.2 [0.9-1.7]
Glucose [mmol/L]	5.2 [4.9-5.4]	5.0 [4.7-5.3]	4.6 [4.3-4.8]	4.7 [4.3-5.2]	5.0 [4.7-5.3]	5.3 [4.9-5.6]	5.5 [5.1-5.8]
Insulin [IU/L]	9.6 [7.4-12.3]	6.8 [4.9-9.3]	–	–	7.5 [6.2-9.4]	7.3 [4.4-11.2]	7.4 [5.2-11.2]

Values are mean (SD) and median [interquartile range] for normally distributed and positively skewed variables, respectively.

## Lipoprotein subclass total lipids

log Extremely large VLDL

log Very large VLDL

log Large VLDL

log Medium VLDL

Small VLDL

Very small VLDL

IDL

Large LDL

Medium LDL

Small LDL

Very large HDL

Large HDL

Medium HDL

Small HDL

## Lipoprotein particle size

VLDL particle size

LDL particle size

HDL particle size

## Apolipoproteins

Apolipoprotein B

Apolipoprotein A-I

ApoB/ApoA1

## Cholesterol

Total C

Non-HDL C

Remnant C

VLDL C

IDL C

LDL C

HDL C

Esterified C

Free C

Esterification %

## Triglycerides

log Total TG

log VLDL TG

IDL TG

LDL TG

HDL TG

## Phospholipids

Total PL

VLDL PL

IDL PL



LDL PL

HDL PL

Phosphoglycerides


Cholines

Sphingomyelin




**Figure 1. Birth weight associations with adult concentrations of lipoprotein lipids.** The associations were adjusted for sex, gestational age, and age at blood sampling, and meta-analysed for 18 288 individuals from 7 cohorts. Association magnitudes are 1-SD lipid concentration per 1-kg lower birth weight. Error bars denote 95% confidence intervals. Filled diamonds indicate  $P < 0.0015$ . Association magnitudes in absolute concentration units and P-values are listed in **Table S1**. Results for individual cohorts are shown in **Figure S5**.





**Figure 2. Birth weight associations with adult fatty acid levels.** The associations were adjusted for sex, gestational age, and age at blood sampling, and meta-analysed for 18 288 individuals from 7 cohorts. Association magnitudes are in units of 1-SD fatty acid measure per 1-kg lower birth weight. Fatty acid ratios are relative to the total fatty acid concentration. Error bars denote 95% confidence intervals. Filled diamonds indicate P<0.0015. Results for individual cohorts are shown in **Figure S5**.


MUFA: mono-unsaturated fatty acids, PUFA: poly-unsaturated fatty acids, DHA: docosahexaenoic acid.



**Figure 3. Birth weight associations with adult metabolite and hormonal concentrations.**

The associations were adjusted for sex, gestational age, and age at blood sampling, and meta-analysed for 18 288 individuals from 7 cohorts. Association magnitudes are in units of 1-SD metabolite concentration per 1-kg lower birth weight. Error bars denote 95% confidence intervals. Filled diamonds indicate  $P < 0.0015$ . Results for individual cohorts are shown in **Figure S5**.

GlycA: Glycoprotein acetyls, SHBG: sex-hormone binding globulin.



**Figure 4.** Resemblance between metabolic association patterns related to lower birth weight and higher adulthood BMI (assessed at the same time as blood sampling for metabolic profiling). The metabolic associations were assessed for the same 18 288 individuals. The red dashed line denotes the linear fit between metabolic associations with lower birth weight and higher BMI. The slope indicates that 1-kg lower birth weight is on average associated with similar metabolic deviations as those linked with 0.92 kg/m<sup>2</sup> higher BMI in adulthood.